CN109789183A - 治疗性多靶向构建体及其用途 - Google Patents

治疗性多靶向构建体及其用途 Download PDF

Info

Publication number
CN109789183A
CN109789183A CN201780060289.8A CN201780060289A CN109789183A CN 109789183 A CN109789183 A CN 109789183A CN 201780060289 A CN201780060289 A CN 201780060289A CN 109789183 A CN109789183 A CN 109789183A
Authority
CN
China
Prior art keywords
peptide
seq
toxin
construct
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780060289.8A
Other languages
English (en)
Chinese (zh)
Inventor
I·莫拉德
H·伊特扎基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aebi Ltd
Original Assignee
Aebi Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aebi Ltd filed Critical Aebi Ltd
Publication of CN109789183A publication Critical patent/CN109789183A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201780060289.8A 2016-09-29 2017-09-27 治疗性多靶向构建体及其用途 Pending CN109789183A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401192P 2016-09-29 2016-09-29
US201662401195P 2016-09-29 2016-09-29
US62/401,192 2016-09-29
US62/401,195 2016-09-29
PCT/IL2017/051094 WO2018061004A1 (en) 2016-09-29 2017-09-27 Therapeutic multi-targeting constructs and uses thereof

Publications (1)

Publication Number Publication Date
CN109789183A true CN109789183A (zh) 2019-05-21

Family

ID=61763358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780060289.8A Pending CN109789183A (zh) 2016-09-29 2017-09-27 治疗性多靶向构建体及其用途

Country Status (8)

Country Link
US (2) US11739163B2 (cg-RX-API-DMAC7.html)
EP (1) EP3518953A4 (cg-RX-API-DMAC7.html)
JP (1) JP7133225B2 (cg-RX-API-DMAC7.html)
CN (1) CN109789183A (cg-RX-API-DMAC7.html)
AU (2) AU2017333442A1 (cg-RX-API-DMAC7.html)
CA (1) CA3037261A1 (cg-RX-API-DMAC7.html)
IL (1) IL265236B2 (cg-RX-API-DMAC7.html)
WO (1) WO2018061004A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) * 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
KR102268983B1 (ko) 2019-09-11 2021-06-24 경북대학교 산학협력단 엔도테린 수용체 억제제에 의한 엑소좀 분비 억제 또는 pd-l1 발현 억제 용도
CN112252362A (zh) * 2020-10-10 2021-01-22 无锡市市政设施建设工程有限公司 基于bim实现地铁车站主体结构盘扣支架搭设的方法
CN121494980A (zh) * 2025-12-12 2026-02-10 北京大学第一医院(北京大学第一临床医学院) 抗胃泌素抗体及其杂交瘤细胞株和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101679526A (zh) * 2007-05-30 2010-03-24 霍夫曼-拉罗奇有限公司 介导癌细胞细胞毒性的人源化和嵌合抗trop-2抗体
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
US20150044210A1 (en) * 2012-02-23 2015-02-12 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040058865A1 (en) 2001-11-26 2004-03-25 Danishefsky Samuel J Homing peptide multimers, their preparation and uses
ES2557286T3 (es) 2003-03-03 2016-01-25 Dyax Corp. Usos de péptidos que se unen específicamente al receptor del HGF (cMet)
WO2005090393A2 (en) 2004-02-09 2005-09-29 The Government Of The United States, As Represented By The Secretary Of Health And Human Services Multimeric protein toxins to target cells having multiple identifying characteristics
DK1915617T3 (da) 2005-07-21 2011-11-21 Aebi Ltd Fremgangsmåder og sammensætninger til identifikation af et peptid, der har en intermolekylær interaktion med et interessemål
US20100021473A1 (en) 2005-12-06 2010-01-28 Domantis Limited Bispecific Ligands With Binding Specificity to Cell Surface Targets and Methods of Use Therefor
ES2544954T3 (es) 2006-02-14 2015-09-07 Universita' Degli Studi Di Siena Péptidos multiméricos ramificados para diagnóstico y terapia de tumores
PE20081140A1 (es) 2006-10-25 2008-09-22 Amgen Inc Agentes terapeuticos a base de peptidos derivados de toxinas
CA2697922A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Compositions that bind multiple epitopes of igf-1r
EP2247615B1 (en) 2008-02-14 2014-07-30 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
EP2352522A4 (en) 2008-11-06 2014-03-05 Univ Washington BISPECIFIC AUXILIARIES FOR INTRA-CELLULAR RELEASE
JP2010154842A (ja) 2008-12-03 2010-07-15 Koji Kawakami Egfrを標的にした新規抗がんキメラペプチド
US8741839B2 (en) 2009-01-18 2014-06-03 The Board Of Trustees Of The Leland Stanford Junior University Polypeptides targeting vascular endothelial growth factor receptor-2 and αvβ3 integrin
US9321820B2 (en) 2009-10-14 2016-04-26 The Regents Of The University Of Colorado Compositions and methods for treating bladder cancer
ES2983470T3 (es) 2010-03-19 2024-10-23 Takeda Pharmaceuticals Co Inhibidores del TFPI y métodos de uso
DK2714738T3 (en) * 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
PL3489254T3 (pl) 2012-04-30 2023-01-30 Biocon Limited Ukierunkowujące/immunomodulujące białko fuzyjne i sposoby jego otrzymywania
JP6103832B2 (ja) 2012-06-25 2017-03-29 Hoya株式会社 Egfr結合性ペプチド
MY186864A (en) 2013-03-12 2021-08-26 Biocon Ltd Fusion immunomodulatory proteins and methods for making same
WO2015010094A1 (en) 2013-07-18 2015-01-22 Eutropics Pharmaceuticals, Inc. Differential bh3 mitochondrial profiling
WO2015023979A1 (en) 2013-08-16 2015-02-19 Equip, Llc Discrete peg constructs
WO2015195721A1 (en) 2014-06-16 2015-12-23 Purdue Research Foundation Compositions and methods for treating cancer
EP3518953A4 (en) * 2016-09-29 2020-10-28 Aebi Ltd. THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND THEIR USES
US20210198319A1 (en) 2017-09-27 2021-07-01 Aebi Ltd. Cytotoxic peptides and conjugates thereof
US20200339629A1 (en) 2019-04-24 2020-10-29 Aebi Ltd. Therapeutic constructs comprising cmet binding peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100151003A1 (en) * 2006-12-21 2010-06-17 Mohit Trikha Egfr binding peptides and uses thereof
CN101679526A (zh) * 2007-05-30 2010-03-24 霍夫曼-拉罗奇有限公司 介导癌细胞细胞毒性的人源化和嵌合抗trop-2抗体
US20150044210A1 (en) * 2012-02-23 2015-02-12 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells

Also Published As

Publication number Publication date
EP3518953A1 (en) 2019-08-07
AU2017333442A1 (en) 2019-04-04
JP2020501513A (ja) 2020-01-23
US20240002547A1 (en) 2024-01-04
AU2022221434A1 (en) 2022-10-06
US11739163B2 (en) 2023-08-29
EP3518953A4 (en) 2020-10-28
IL265236B1 (en) 2023-07-01
US20190225711A1 (en) 2019-07-25
CA3037261A1 (en) 2018-04-05
IL265236A (en) 2019-05-30
IL265236B2 (en) 2023-11-01
WO2018061004A1 (en) 2018-04-05
JP7133225B2 (ja) 2022-09-08

Similar Documents

Publication Publication Date Title
JP6857736B2 (ja) 新規なエクソソーム系抗癌剤
Feng et al. Multistage-responsive nanovehicle to improve tumor penetration for dual-modality imaging-guided photodynamic-immunotherapy
US20240002547A1 (en) Therapeutic multi-targeting constructs and uses thereof
WO2019189780A1 (ja) 癌の治療及び/又は予防用医薬組成物
Liang et al. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles
CN109803642A (zh) 新型纳米笼及其用途
CN110698565A (zh) 靶向肿瘤的CD38-pHLIP融合肽
WO2021182573A1 (ja) 癌の治療及び/又は予防のための医薬品
Wang et al. Nanotechnology applications in breast cancer immunotherapy
ES2874668T3 (es) Conjugados anticuerpo-fármaco dirigidos a uPARAP
Chen et al. Chimeric peptide engineered bioregulator for metastatic tumor immunotherapy through macrophage polarization and phagocytosis restoration
US11833204B2 (en) Visible light-activatable nanoparticles for cancer immunotherapy and use thereof
CN111087465A (zh) 一种针对密蛋白6的抗体偶联药物及应用
Hunt Precision targeting of intraperitoneal tumors with peptideguided nanocarriers
WO2021182571A1 (ja) 癌の治療及び/又は予防のための医薬品
WO2021182572A1 (ja) 癌の治療及び/又は予防のための医薬品
WO2021182574A1 (ja) 癌の治療及び/又は予防のための医薬品
EP2833900B1 (en) Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
CN113244175B (zh) 一种免疫囊泡美登素偶联物及其制备方法与应用
EP4146243A1 (en) Anti-cancer proteins
US20200339629A1 (en) Therapeutic constructs comprising cmet binding peptides
US20210198319A1 (en) Cytotoxic peptides and conjugates thereof
CN106632688A (zh) 一种用于修饰微泡的多肽以及靶向gbm的药物制剂
KR20160069667A (ko) 상피성장인자 수용체를 표적으로 하는 신규 항암제
CN115025217B (zh) 干细胞裂解物联合活性多糖以及酪氨酸酶抑制剂在制备药物或化妆品中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190521

WD01 Invention patent application deemed withdrawn after publication